These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24150219)

  • 21. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the
    Brusson M; Cochet S; Leduc M; Guillonneau F; Mayeux P; Peyrard T; Chomienne C; Le Van Kim C; Cassinat B; Kiladjian JJ; El Nemer W
    Haematologica; 2017 Jul; 102(7):e241-e244. PubMed ID: 28385780
    [No Abstract]   [Full Text] [Related]  

  • 25. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
    King KY; Matatall KA; Shen CC; Goodell MA; Swierczek SI; Prchal JT
    Exp Hematol; 2015 Oct; 43(10):912-918.e2. PubMed ID: 26072330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
    Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
    Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
    Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
    Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.
    Abe M; Funakoshi-Tago M; Tago K; Kamishimoto J; Aizu-Yokota E; Sonoda Y; Kasahara T
    Int Immunopharmacol; 2009 Jul; 9(7-8):870-7. PubMed ID: 19327411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Austrian recommendations for the management of polycythemia vera.
    Burgstaller S; Buxhofer-Ausch V; Sliwa T; Beham-Schmid C; Gastl G; Geissler K; Melchardt T; Krauth M; Krippl P; Petzer A; Rumpold H; Wölfler A; Gisslinger H
    Wien Klin Wochenschr; 2018 Sep; 130(17-18):535-542. PubMed ID: 30027395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
    Lu M; Xia L; Li Y; Wang X; Hoffman R
    Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
    Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
    Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
    Karkucak M; Yakut T; Ozkocaman V; Ozkalemkas F; Ali R; Bayram M; Gorukmez O; Ocakoglu G
    Mol Biol Rep; 2012 Sep; 39(9):8663-7. PubMed ID: 22722988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.
    Margolskee E; Krichevsky S; Orazi A; Silver RT
    Haematologica; 2017 Mar; 102(3):e97-e99. PubMed ID: 27810993
    [No Abstract]   [Full Text] [Related]  

  • 39. JAK2V617F allele burden is associated with transformation to myelofibrosis.
    Koren-Michowitz M; Landman J; Cohen Y; Rahimi-Levene N; Salomon O; Michael M; Amariglio N; Nagler A
    Leuk Lymphoma; 2012 Nov; 53(11):2210-3. PubMed ID: 22524513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
    Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.